Ascites is the formation of excessive fluid in the space surrounding the organs in the abdomen, especially in the peritoneal cavity. It occurs because of the body is unable to remove fluids it produced. Ascites can occur in normal conditions as well as in cancer condition. When ascites occurs due to cancer, often called malignant ascites or malignant peritoneal effusion. Malignant cells causes irritation in the layers of the abdomen and it leads to production of excessive body fluids. Usually, lymph glands drain excessive body fluids from the body, but, in ascites condition, lymph glands become blocked and it leads to outbreaks of ascites symptoms include loss of sleep, skin problems, fatigue, low blood pressure, and problems with self-esteem. Malignant ascites caused by different health conditions such as, irritation of the thin membrane of abdomen, destruction in lymphatic system, and disturbances in the liver function due to the cancer cells.
Symptoms of malignant ascites depends on various factors. Main symptoms in the malignant ascites includes swelling of the abdomen, feeling of bloating, abdominal discomfort or pain, fatigue, shortness of breath, weight gain, constipation and ankle or leg swelling.
For diagnosis of malignant ascites, x-ray test, physical examination, ultrasound and CT scans are available. However, physical examinations is not effective in an obese patient cases.
Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1658
For the treatment malignant ascites, diuretics, chemotherapy, paracentesis and surgeries are available. Diuretics are used for the removal of more fluids from the body and it is effective treatment in this disease condition. Paracentesis is a process of removal of body fluid by using a catheter and it is used when the diuretics are not effective and the patients are suffering from breathing problems. Food and Drug Administration (FDA), recently approved PleurX catheter, for the treatment of malignant ascites. Chemotherapy drugs are used in the treatment of malignant ascites and physician give drugs directly to the intra peritoneal cavity of the patient for more effective.
Malignant Ascites market has been classified on the basis of treatment and distribution channel
Malignant Ascites by Treatment Type
- Chemotherapy
- Diuretics
- Paracentesis
- Surgery
Malignant Ascites by Distribution Channel
- Hospitals
- Diagnostic Centres
- Clinics
- Retail Pharmacies
- Ambulatory Surgical Centre
Lack of awareness about the disease is major restraint for malignant ascites market, especially in the obese patient the diagnosis of disease is slightly difficult by physical examination.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1658
Increase in the prevalence rate of various cancers, ovarian cancer, breast cancer, bowel cancer, stomach cancer, pancreatic cancer, mesothelioma in the peritoneum, lung cancer, liver cancer and womb cancer is expected to drive the malignant ascites market owing to the chances of ascites is high in patients who are suffering from these cancers.
Depending on geographic region, Malignant Ascites market is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is estimated to contribute maximum revenue share in the global market of Malignant Ascites followed by Europe. Asia Pacific regions are expected to grow at a higher growth rate owing to high occurrence of cancer diseases. Middle East & Africa is expected to show a healthy growth rate in a forecast period.
Key players of malignant ascites market are BD, Actavis elizabeth llc, Sandoz inc, Mylan pharmaceuticals inc, Trion Pharma, GE healthcare, Siemens AG, and Fresenius Biotech.
Browse full report: http://www.futuremarketinsights.com/reports/malignant-ascites-market
Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Email:sales@futuremarketinsights.com
Website: www.futuremarketinsights.com
Press Release: http://www.futuremarketinsights.com/press-release
